Patients with Crohn's disease [CD] harbour an increased number of adherent-invasive E. coli [AIEC]. The strain LF82, identified in the ileal mucosa of CD patients, has been extensively studied for pathogenic mechanisms. However, understanding of the interaction of LF82 with the intestinal mucosa of CD patients is lacking. Methods: Here, we investigated the importance of long polar fimbriae [LPF] type 1 pili and the carcinoembryonic antigen-related cell-adhesion molecule 6 [CEACAM6] for translocation of LF82 in an in vitro model of follicle-associated epithelium [FAE], and in the FAE and villus epithelium [VE] of patients with CD and controls, using Ussing chambers. Results: Significantly greater LF82 passage occurred in the FAE model compared with in the VE Caco-2cl1 mono-culture. Moreover, bacterial translocation was inhibited by either LPF disruption or preincubation with anti-CEACAM6 antibody. Tissue mounted in Ussing chambers showed significantly higher LF82 passage in FAE from patients with CD compared with control FAE, that was diminished in LF82 lacking LPF and by blocking host CEACAM6. Interestingly, addition of LF82 to the CD FAE tissues significantly increased paracellular permeability [of 51 Chromium-EDTA] compared with baseline, and the increase was inhibited by anti-CEACAM6. Immunofluorescence and immunoblots showed higher expression of CEACAM6 in FAE of patients with CD compared with in FAE from controls.
Introduction
Crohn's disease [CD] is an inflammatory bowel disease [IBD] with a multifactorial aetiology, with evidence that genetic, immunological, and environmental factors all contribute to the pathogenesis of the disease. 1, 2 There is a lack of defence against bacteria in CD, leading to mucosal barrier dysfunction that is a combination of increased transcellular 3, 4 and paracellular permeability. 5, 6 Postoperative recurrence of CD remains a major clinical challenge. Studies have shown alterations in the mucosal barrier of the neo-terminal ileum at the time of bowel resection, 3, 7, 8 and CD recurrence is triggered by luminal contents in the terminal ileum proximal to the ileocolonic anastomosis, 9 even during the first post-operative day. 10 The earliest observable signs of CD are aphthoid lesions 11 that are preceded by ultra-structural erosions in the follicle-associated epithelium [FAE] overlying the Peyer's patches in the ileum. 12 The FAE differs from the surrounding villus epithelium [VE] , and the most distinguishing feature of the FAE is the presence of membranous/ microfold [M] cells, which are specialized for the sampling and transport of antigens and microorganisms. 13 Several microorganisms, particularly invasive bacteria such as Yersinia and Salmonella, 14, 15 take advantage of the transcytotic characteristics of M cells to cross the intestinal barrier. The molecular mechanism behind the ability of these bacteria to interact with and penetrate the M cells is only partially known, but the expression of long polar fimbriae [LPF] has been highlighted. 15 We previously showed that human FAE is not only structurally but also functionally distinct from regular VE, with enhanced transport of antigens and bacteria into the underlying lymphoid tissue. 16 In addition, we showed an enhanced bacterial uptake in CD FAE compared with that in non-IBD controls, 8 with an increased internalization by pro-inflammatory dendritic cells. 7 The bacterial uptake was both transcellular and paracellular in CD FAE, in contrast to that in controls, in which only transcellular uptake occurred.
Luminal enteric bacteria are considered to be the most important inflammation-driving environmental factor in CD. 17, 18 Studies in CD patients have shown various changes in the luminal microbiota, with a possible link to local inflammation. 19, 20 One potential pathogenic group of Escherichia coli has been identified that can adhere and invade the enterocytes and has been designated adherent-invasive E. coli [AIEC]. [21] [22] [23] AIEC have been detected in CD patients in several countries, 21, 22, [24] [25] [26] and the concentration of bacteria increases progressively with the severity of the disease. 18, 27 A specific strain of AIEC, E. coli LF82, has been identified in the ileal mucosa of CD patients and has been shown to invade the lamina propria and to replicate within macrophages. 18, 22, 23, 28 Moreover, Fang et al. 29 studied the abundance and properties of E. coli strains in a series of samples from a CD patient, using metagenomics-based strain-level analysis. Their results showed that the abundance and dominance of the specific E. coli strain ST1, similar to LF82, varied over time and was correlated with inflammation status.
A possible explanation for the increased numbers of AIEC associated with CD is the increased expression of the carcinoembryonic antigen-related cell-adhesion molecule 6 [CEACAM6] in the brush border of ileal enterocytes in CD patients: CEACAM6 is a receptor for AIEC, binding to the intestinal mucosa via type 1 pili. 30 Interestingly, in a CEABAC10 transgenic mouse model [expressing human CEACAMs], mice infected with LF82, but not with nonpathogenic E. coli, showed a 3-fold increase in intestinal permeability and disrupted mucosal integrity with a type 1 pili-dependent mechanism. 31 Moreover, we previously showed that E. coli expressing LPF translocate across an in vitro model of FAE and interact with murine and human Peyer's patches. 32 Although a number of studies have elucidated the interaction of LF82 with the intestinal epithelium, studies of mechanisms of invasion through the human intestinal mucosa of CD patients have so far been lacking. In the present study, to complement and extend findings from cell lines and mice, we sought to study LF82 translocation and the importance of LPF and CEACAM6 in vitro and ex vivo in the FAE and VE of CD patients and non-IBD controls.
Materials and methods

Bacterial strains
The AIEC reference strain LF82 and isogenic mutant with the lpfA gene deleted, LF82 ∆lpfA , were used. 21, 23, 32 Isogenic mutants were generated with a PCR product using the method described by Datsenko et al. 33 Bacteria were grown in Luria-Bertani [LB] broth overnight at 37°C without shaking. Plasmid pFPV25.1 was used to make bacterial strains expressing green fluorescent protein [GFP]. 34 Before experiments started, the effect of GFP labelling on bacterial growth was tested. GFP-labelled LF82 and unlabelled LF82 were plated in duplicates on LB agar plates supplemented with 100 µg/ml ampicillin, air dried for 30 min, and incubated at 37°C for 18 h. Colonies on each plate were counted and bacterial growth was evaluated by comparing the colony-forming units [CFUs] for GFP-labelled and unlabelled E. coli LF82. Results showed no difference in growth between GFP-labelled [178 CFU] and unlabelled [185 CFU] E. coli LF82. In addition, we previously showed 32 that there is no difference in growth between LF82 and LF82 ∆lpfA . GFP labelling of Salmonella typhimurium was prepared as previously described for E. coli HB101. 35 
In vitro experiments
Cell cultures
Co-culture model of human FAE
To study the translocation of AIEC LF82 in human FAE, an in vitro co-culture model was initially used, as described by Kernéis et al., showing that co-culture of Peyer's patch lymphocytes and intestinal epithelial cells can trigger epithelial cell conversion to an M cell-like phenotype. 36 We previously established a modified version of this co-culture. 37 Briefly, intestinal epithelial Caco-2cl1 cells were grown for 14 - 
Verification of the model FAE
To confirm the transformation to M cells, the TER was measured daily; to be considered transformed, the TER should be at ≥10% lower in the co-culture model compared with in the Caco-2cl1. 38 In the present study, we showed a median of 14.2% lower TER in the co-culture model compared with in the Caco-2cl1, confirming the transformation of epithelial cells to M cell-like cells (median [25th-75th percentiles] Ω × cm 2 , Caco-2cl1: 588 [542-631]; co-culture: 504 [463-551]), p < 0.05, n = 10. In addition, filters were processed for scanning electron microscopy [JSM 840, JEOL, Japan] that confirmed Caco-2cl1 cell transformation to FAE-like epithelium, as shown by areas of sparse irregular microvilli on the apical surface, indicating an M cell-like morphology [ Figure 1A ]. To further verify transport function in the model FAE, transcytosis of live GFP-Salmonella typhimurium was studied. Salmonella typhimurium has been shown to translocate from the apical to the basolateral side of M cell monolayers at a significantly higher rate compared with Caco-2cl1 monolayers. 38 Experiments with Salmonella confirmed the transformation to model FAE by showing an increased translocation of Salmonella in the basolateral medium of co-culture monolayers compared with Caco-2cl1, measured by fluorimetry, and by plating basolateral samples containing translocated Salmonella on LB-agar overnight at 37°C, in conditions of 5% CO 2 , followed by assessment of CFU numbers through modification of a scoring system previously used in our group. 39 Score 1 represented least CFUs and 5 represented most CFUs, and the plates in between were designated as having Scores 2, 3, or 4. Figure 1B All experiments were performed with 6-10 independent settings and each experiment was performed in triplicate.
Translocation of E. coli LF82 and LF82 ∆lpfA
Before and after transport experiments, the TER was measured to check the monolayer integrity. Upon M cell transformation, cultures were exposed in triplicate on the apical sides to 10 8 live GFP-labelled E. coli LF82 or E. coli LF82 ∆lpfA . After 3 h, the TER was measured and basolateral samples were collected in triplicate. Translocated LF82 was measured by fluorimetry and CFU counting. , using a scoring system. Basolateral samples containing translocated E. coli LF82 were plated on LB-agar overnight at 37°C, in 5% CO 2 conditions, followed by assessment of the number of CFUs, using a scoring system in which Score 1 represented the least CFUs and Score 5 represented the most CFUs, the plates in between being scored as Scores 2, 3, or 4. This figure shows representative plates for each score. Score 4 represents plates with >500 CFUs, in which colonies were uncountable, but discernible colonies were evident.
All experiments were performed with 6-10 independent settings and each experiment was performed in triplicate.
Effects of anti-CEACAM6 on LF82 translocation
It was previously shown that the Caco-2cl1 cells used in the present study express CEACAM6. 30 The mono-and co-cultures were divided into two groups: [i] those infected with 10 8 E. coli LF82; [ii] those pre-treated on the apical side with 21 ng/ml mouse monoclonal antihuman CEACAM6 [Pierce, Thermo Fisher Scientific, Sweden] for 20 min prior to administration of 10 8 LF82. After 3 h, the TER was measured, and basolateral samples were collected and analyzed as above. Experiments were performed with 6-10 independent settings and each experiment was performed in triplicate. Before experiments started, the concentration of the anti-CEACAM6 antibody was optimized. Ussing chamber experiments were run with concentrations 7, 21, 35, and 42 ng/ml. The highest peak in blocking of bacterial passage was achieved with 21 ng/ml. To verify the specificity of anti-CEACAM6, experiments were also performed with an irrelevant antibody [Mouse IgG1 Isotype Control, Pierce]. These experiments were performed with three of the 6-10 independent settings. Experiments were performed as described for anti-CEACAM6, but in addition, 21 ng/ml of the irrelevant antibody was added to three extra wells.
Human experiments
Patients and ethics
Specimens from the neo-terminal ileum, or terminal ileum next to the ileocaecal valve, were taken during surgery from 27 patients with CD and 29 patients with non-inflammatory conditions serving as non-IBD controls, at the University Hospital of Linköping.
Details of anti-inflammatory medication, indication for surgery, Montreal classification and pre-operative C-reactive protein for the CD patients (median age 51 years [range 18-81], 16 men) are given in Table 1 . The non-IBD controls were colon cancer patients (70 years [range 46-88], 15 men). The patients had no generalized disease and none of them had received preoperative chemo-or radiotherapy. The Regional Ethical Review Board, Sweden, approved the study and all subjects gave their written informed consent.
Surgical specimens were put in ice-cold oxygenated Krebs buffer [115 mM NaCl, 1.25 mM CaCl 2 , 1.2 mM MgCl 2 , 2 mM KH 2 PO 4 , and 25 mM NaHCO 3 , pH 7.35] immediately after division of the ileocolic artery, and transported to the laboratory for stripping of external muscle and myenteric plexus. Microscopic identification of the VE and FAE were done as previously described. 35 Segments of the FAE and VE were obtained from ileum of the same individual and run in parallel in the Ussing chamber experiments, western blot, and immunofluorescence analyses.
Ussing chamber experiments
Segments of the VE and FAE were mounted in modified Ussing chambers [Harvard apparatus Inc., Holliston, MA] 40 as previously described. 35 Briefly, mucosal compartments were filled with 1.5 ml cold 10 mM mannitol in Krebs buffer and the serosal compartments with 10 mM glucose in Krebs buffer, and continuously oxygenated at 37°C, while being mixed by gas flow. Chambers were equilibrated for 40 min to achieve steady state conditions, and L3  B2  <10  61  m  mesalazine  stenosis  A3  L1  B2  <10  81  m  none  fistula  A3  L1  B3  17  44  f  none  stenosis  A1  L3  B2  <10  39  f  none  stenosis  A2  L3  B2  <10  19  m  budenoside  stenosis  A2  L3  B2  <10  49  m  none  stenosis  A2  L3  B3  13  51  f  prednisolone, azathioprine  stenosis  A2  L3  B2  <10  36  f  budenoside  ileitis, stenosis  A2  L3  B2  <10  71  m  none  stenosis  A3  L3  B2  <10  68  m  prednisolone  stenosis  A3  L1  B2  <10  18  m  sulfasalazine, azathioprine  stenosis  A1  L3  B2  52  42  f  certolizumab  stenosis  A2  L3  B2  <10  39  f  budenoside  stenosis  A2  L1  B2  10  49  m  monoclonal antibody  stenosis  A2  L2  B3  <10  61  m  mesalazine  stenosis  A3  L1  B2  <10  68  m  prednisolone  stenosis  A3  L1  B2  <10  73  f  adalimumab  stenosis  A3  L1  B2  12  36  f  prednisolone, mesalazine  stenosis  A2  L3  B2  <10  71  m  none  stenosis  A3  L1  B2  <10  69  m  mesalazine, prednisolone  stenosis, cecal infl.  A2  L1  B2  <10  45  m  methotrexate, mesalazine  ileocolic resection  A2  L3  B2  <10  22  m  infliximab  ileocolic resection  A2  L1  B3  <10  74  f  none  ileocolic resection  A3  L1  B2  12  53  m  enteral nutrition  ileocolic resection  A2  L3  B3  <10  51  m  none  ileocolic resection  A2  L1  B2  <10  61  f  prednisolone  ileocolic resection  A2  L3  B2  12 MC= Montreal Classification; A1: <16; A2: 16-40; A3: >40; L1: ileum; L2: colon; L3: ileum and colon; B2: strictures; B3: perforations; Pre-op P-CRP: preoperative plasma C-reactive protein.
barrier properties were then studied for 120 min. The experiments were performed in open circuit conditions, with the transepithelial potential difference [PD], short-circuit current [Isc], and TER being monitored every second minute using one pair of Ag/AgCl electrodes with agar-salt bridges and one pair of current-giving platinum electrodes. At the conclusion of the experiments, 10 µM of the Clsecretagogue forskolin was added to the chambers, and the electrophysiological response was monitored to ensure continued viability of the tissues. ] non-IBD controls were mounted in Ussing chambers for analysis of bacterial passage. After equilibration, live GFP-E. coli LF82 or GFP-E. coli LF82 ∆lpfA were added to the mucosal side to a final concentration of 10 8 CFUs/ml. Two tissues received LF82, two LF82 ∆lpfA , and two served as Krebs-only controls. Serosal samples of 1.5 ml were collected at the start and at the end of the experiment [at time 120 min]. Bacterial translocation was determined by fluorimetry and recalculated as bacteria/chamber. In addition, basolateral samples were plated on LB-agar for CFU counting as described for in vitro experiments. Blanks and samples were run in duplicate and measured against a standard curve.
Bacterial translocation
Paracellular permeability
Segments of the FAE and VE [from nine controls and eight patients with CD, as detailed above] were mounted in Ussing chambers, as described for the bacterial passage experiments. For paracellular studies, 34 µCi/ml of the inert probe 51 Chromium-EDTA [ 51 Cr-EDTA], mw 384 Da [Perkin Elmer, Boston, MA], was added to the mucosal side of all chambers, together with bacteria, or Krebs as a vehicle. At 0, 60, and 120 min after the start, serosal samples [300 µl] were collected and replaced with an equal volume of Krebs. 51 Cr-EDTA was measured in a gamma counter [1282 Compugamma, LKB, Bromma, Sweden], and permeability was calculated during the 60-120 min period and given as P app [apparent permeability coefficient; cm/s × 10 -6 ]. Chambers mounted with VE and FAE from one non-IBD control, and VE from one CD patient, were excluded due to technical problems. 35 
Blocking with anti-CEACAM6
To study the influence of CEACAM6 on LF82 translocation through the FAE, segments from 10 controls (72 years [63-86], 6 men) and nine patients with CD (45 years [18-72], 4 men) were mounted in Ussing chambers. After 20 min, buffers were replaced and mouse anti-human CEACAM6 [Pierce] was added to the mucosal sides to a final concentration of 21 ng/ml. After 20 more minutes, GFP-LF82 and 51 Cr-EDTA were added to the mucosal sides and samples were collected as described above.
To verify the specificity of anti-CEACAM6 in the human set-up, experiments were, as for in vitro studies, implemented with the irrelevant antibody [Pierce] . Experiments were performed on the FAE from three patients with CD (43 years [39-49] 1 man) and three controls (72 years [67-76], 3 men). Ussing chamber studies were performed as described above, but in addition, 21 ng/ml of the irrelevant antibody was added to two extra chambers.
As well as the experiments above, segments of the FAE from two controls (69 years [67-72], 2 men) and two patients with CD (53 years [51-55], 1 man) were mounted in Ussing chambers. After 20 min of pre-incubation with 21 ng/ml of anti-CEACAM6, segments were treated with 10 8 CFUs/ml of the non-AIEC E. coli HS and added to the mucosal sides, instead of AIEC E. coli LF82. Three sections per patient were evaluated in a blinded fashion for CEACAM6 expression in a Nicon-Eclipse-E800 fluorescence microscope equipped with a Nikon DS-Ri1-digital camera. In total, 20 pictures/section were obtained, and three epithelium types were identified: VE, FAE, and adjacent-VE. The adjacent-VE is defined as the VE lining the first villus next to the FAE, and differs from the VE further away from the dome; there is higher expression of the cell adhesion protein and bacterial co-receptor CD9 in adjacent-VE compared with villi further away, which expresses no, or very little, CD9. 16 By using ImageJ software [NIH] the epithelial linings in each picture were encircled and a mean fluorescence intensity was calculated. From each patient/control, a mean value was calculated from the FAE, VE, and adjacent-VE, and then a median value was calculated for all patients/controls.
Quantification of CEACAM6 in tissue lysates by western blotting
Statistical analysis
According to the D'Agostino-Pearson omnibus normality test, the data were judged as non-parametric, and accordingly data are given as the median [25th-75th percentiles]. Comparisons between two groups were carried out using the Mann-Whitney U test. The Wilcoxon matched-pairs signed-rank test was used for paired comparisons [in vitro TER and individual comparisons of anti-CEACAM6 effects ex vivo]. Differences with p < 0.05 were considered significant. Statistical analyses were performed using GraphPad Prism 7 Software [CA, USA].
Results
In vitro
Lower TER by E. coli LF82 and increased translocation in model FAE
E. coli LF82 infection resulted in a 19.5% decrease in TER in the Caco-2cl1 model compared with that in control wells with no bacteria added, p < 0.05, and there was a 5.7% decrease in the co-culture model, p < 0.05 [ Table 2 ]. Translocation of LF82 was increased by 42.9% in the co-culture compared with that in Caco-2cl1, p < 0.05 [ Figure 2A ]. The greater passage of LF82 was confirmed by CFU counting of the basolateral media, which showed 50% more CFUs in the co-culture compared with in Caco-2-cl1, p < 0.005 [ Figure 2B ].
Translocation of E. coli LF82 was dependent on LPF expression and CEACAM6
Transepithelial passage of LF82 ∆lpfA showed only a slightly decreased passage of 4.1% compared with LF82 in Caco-2cl1 epithelial monolayers; however, in the FAE co-culture there was a 29.3% decreased passage compared with in corresponding cells given LF82, p < 0.05 [ Figure 2C ]. Overnight culture of the basolateral media confirmed the fluorimetry results, showing a 25% [non-significantly] decreased number of LF82 ∆lpfA colonies compared with LF82 in Caco-2cl1, and a 50% decrease of LF82 ∆lpfA colonies compared with LF82 in the co-culture, p < 0.005 [ Figure 2D ].
Similarly to LF82, LF82 ∆lpfA decreased the TER, both in Caco-2cl1 [8.6%] and in the co-culture [10.9%], p < 0.05 [ Table 2 ]. This indicated that the LF82 lacking LPF passes through the cells to a lesser extent, but still decreases the TER. Comparisons showed no significant difference in the effects on the TER between LF82 and LF82 ∆lpfA .
Pre-incubating the epithelial cells with anti-CEACAM6 antibodies prior to LF82 infection showed only a slightly decreased translocation of 6.9% in Caco-2cl1 monolayers; however, in the model FAE, there was a 51.7% decreased passage [p < 0.05] [ Figure 2E ]. Preincubation with an irrelevant antibody had no effect on LF82 translocation [ Figure 2E ]. These data were confirmed by CFU counting, which showed fewer LF82 colonies in the co-culture, p < 0.05, and close to statistically significantly fewer LF82 colonies in Caco-2cl1, p = 0.075, whereas no effect was seen with the irrelevant antibody [ Figure 2F ]. Pre-incubating cells with anti-CEACAM6 antibodies prior to infection with LF82 prevented the drop in TER [ Table 2 ].
Based on the in vitro results, we set up ex vivo human experiments to further evaluate the role of CEACAM6 and LPF in LF82 uptake, and to compare tissues from patients with CD with those from controls.
Human tissues ex vivo
After equilibration, the PD was stable in all CD and control tissues, confirming their viability. Addition of LF82 had no effect on TER or Isc at any time point in the FAE or in the VE. Table 3 shows the values at 90 min as a representative time point; however, values were similar at 30, 60, and 120 min.
Increased translocation of LF82 through CD ileum
There was an increased translocation of E. coli LF82, as assessed by fluorometry, in patients with CD compared with controls, both in the FAE [p < 0.0005] and the VE [p < 0.005], and the translocation was greater across the FAE than across the VE in both groups, p < 0.05 [ Figure 3A ]. Overnight culture of serosal samples confirmed the increased LF82 translocation in the FAE of patients with CD compared with that of controls, p < 0.05 [ Figure 3B ].
Translocation of LF82 through human ileum was dependent on LPF and CEACAM6
To study the impact of LPF on LF82 translocation, experiments were performed with LF82 and its mutant lacking LPF. Results showed that there was significantly less translocation of LF82 ∆lpfA than of LF82 through the FAE of patients with CD, p < 0.005, and through that of controls, p < 0.05, but there was only a non-significant difference in VE, p = 0.1, in both CD patients [ Figure 3C ] and controls [ Figure 3D ]. There was no significant difference in LF82 ∆lpfA translocation between the epithelial types. Passage of LF82 ∆lpfA was higher in patients with CD compared with controls, both in VE and FAE, p < 0.0005 [ Figure 3C , D]. These results indicate that LPF plays a greater role in LF82 uptake in FAE, and in patients with CD compared with controls. Overnight culture of samples from chambers mounted with FAE confirmed the increased LF82 translocation 2 . Comparisons between two groups were done with the Mann-Whitney U test, and the Wilcoxon matched-pairs signed-rank test was used for paired comparisons, *=p < 0.05 compared with time point 0 h for each treatment, respectively. All experiments were performed in 6-10 independent settings, and each experiment was performed in triplicate. compared with LF82 ∆lpfA in patients with CD, and it also showed a significant difference in controls, p < 0.05 [ Figure 3B ].
To further investigate impacts on LF82 translocation, experiments were performed with and without a blocker for CEACAM6. Results showed a 61% decrease in LF82 translocation after blocking of CEACAM6 in FAE from patients with CD, p < 0.05, and a 39% decrease in controls, p = 0.064 [ Figure 4A ]. Pre-incubation with the irrelevant antibody showed no effect on LF82 translocation [ Figure 4A ]. When comparing the effect of anti-CEACAM6 individually, using the Wilcoxon matched-pairs signed-rank test, there was a significant decrease in LF82 translocation in both patients with CD, p < 0.005, and controls, p < 0.005; however, the decrease was significantly higher in patients with CD, p < 0.05 [ Figure 4B ]. In FAE segments treated with the non-AIEC E. coli HS instead of AIEC E. coli LF82, no effect on translocation by pre-incubation with anti-CEACAM6 was observed, either in patients with CD {(E. coli 
Increased 51 Cr-EDTA permeability in CD FAE by LF82 was dependent on CEACAM6
There was no significant difference when comparing baseline 51 Cr-EDTA permeability between patients with CD and controls, or any significant differences between VE and FAE within the groups [ Figure 5A , B]. Interestingly, when adding LF82 to the chambers, 51 Cr-EDTA permeability increased compared with baseline in the FAE of patients with CD, p < 0.005. In the VE of patients with CD, there was also an increase in 51 Cr-EDTA permeability, but the increase did not reach statistical significance, p = 0.078. In controls, there were no significant effects on 51 Cr-EDTA permeability from LF82. The LF82-induced increase in paracellular permeability to Segments of villus epithelium [VE] and follicle-associated epithelium [FAE] from nine non-inflammatory bowel disease [IBD] controls and eight patients with Crohn's disease were mounted in Ussing chambers and exposed to vehicle or E. coli LF82. Comparisons were made with the Mann-Whitney U test. The values above, median [25th-75th percentiles], represent the recordings at 90 min, but there were no significant effects on TER or Isc by E. coli LF82 at any time point. 51 Cr-EDTA through the FAE of patients with CD, p < 0.05, reverted to a normal level in tissues pre-incubated with anti-CEACAM6, p < 0.005 [ Figure 5C ]. There was no effect on electrophysiology by blocking of the CEACAM6 receptor [results not shown]. Addition of LF82 ∆lpfA to the chambers had no effect on permeability to 51 Cr-EDTA in either patient group [ Figure 5A , B].
Increased expression of CEACAM6 in patients with CD
To define differences in CEACAM6 levels between patients with CD and controls, epithelial tissues were analyzed by western blotting. Analysis of tissue lysates revealed higher levels of CEACAM6 in the FAE of patients with CD compared with FAE from non-IBD controls, p < 0.05, but no significant difference could be observed in VE, p = 0.23 [ Figure 6 ]. There was no significant difference between VE and FAE of patients with CD, p = 0.16; however, in controls the expression was significantly higher in FAE compared with VE, p < 0.05 [paired comparisons] [ Figure 6 ]. In FAE from two patients, the expression of CEACAM6 was considerably higher compared with the median expression; however, these values were not judged to be outliers by the program and were therefore included in the results.
In order to confirm the western blotting results, and also to study the epithelial expression of CEACAM6 exclusively, sections of VE and FAE were stained for CEACAM6 by immunofluorescence. Representative staining is shown in Figure 7A . Analysis in ImageJ showed significantly higher apical CEACAM6 expression in FAE, VE, and adjacent-VE of patients with CD compared with controls [ Figure 7B ]. In both CD patients and controls, there was higher apical CEACAM6 expression in FAE compared with VE, p < 0.05 [ Figure 7C ].
Discussion
Accumulating data indicate a central role for the intestinal microbiota in triggering inflammation in CD patients. Strains of E. coli have been associated with the occurrence of CD, 41 and several isolated from CD patients have adherent-invasive properties, so are called AIEC. 18, [21] [22] [23] 28 Here, we show for the first time that translocation of AIEC strain LF82 across the intestinal epithelium is enhanced in patients with CD compared with non-IBD controls, extending data from previous studies with epithelial cell lines. The increased uptake of wildtype LF82 in patients with CD was counteracted by anti-CEACAM6 antibodies and was not apparent in the strain lacking LPF, suggesting use of CEACAM6 or LPF antibodies could be a potential therapeutic approach to preventing AIEC-evoked recurrence in CD. Our initial in vitro experiments confirmed previous findings, 32 showing higher LF82 translocation in the FAE co-cultures compared with Caco2-cl1 mono-cultures. The increased bacterial passage in the FAE model might be due to the presence of M cell-like cells, but it could also be due to more abundant CEACAM6 expression, or both. Experiments with tissues mounted in Ussing chambers revealed a 3.5-fold higher LF82 translocation in FAE from patients with CD compared with controls, and more translocation of LF82 in FAE compared with VE, in both CD patients and controls. This confirms our previous findings with tissues from control patients, 42 that LF82 targets FAE at a higher rate than VE, and uniquely illustrates the greater vulnerability of tissue from patients with CD to AIECevoked increases in permeability, compared with that from controls.
The next step was to study the influence of LPF on LF82 translocation. In vitro experiments showed the mutant LF82 ∆lpfA to pass at a lower rate compared with LF82 through model FAE, but not through Caco2-cl1. Ussing experiments on human tissues revealed higher LF82 translocation compared with LF82 ∆lpfA in FAE of both CD patients and controls. In VE, there was only a significant difference in patients with CD. These findings support the contention that LPF is crucial for E. coli LF82 translocation through the intestinal mucosa; moreover, LPF may be more important in VE during inflammation, since non-IBD controls showed no significant difference in passage between LF82 and its mutant. To our knowledge, there is no data supporting a direct interaction between LPF and CEACAM6, but the fact that LPF promotes translocation in the absence of CEACAM6 suggests that LPF is not using this protein as a receptor.
Our findings might be important for understanding the development of CD, since the earliest observable signs of CD are aphthoid lesions 11 preceded by ultrastructural erosions in the FAE. 12 With respect to CD pathogenesis or reactivation, we speculate that this could begin with dysbiosis and a bloom of [or increased] AIEC strains 26 having an enhanced affinity to FAE in patients with CD and an increased rate of translocation into Peyer's patches. These events could lead to enhanced antigen presentation in Peyer's patches and local pro-inflammatory immune responses. 7, 43 Our findings could open up possibilities for new treatments targeting LF82 and other AIEC strains. Treatment with antibiotics is not optimal, because antibiotic resistance is increasing, and the risk of dysbiosis is evident. 44 However, the promising results of targeting the adhesive properties of AIEC in IBD are supported by studies using synthetic mannosides, 45 which have been shown to reduce LF82 in mouse gut, leading to decreased inflammatory responses. 46 In addition, Galtier et al. 47 recently showed that virulent bacteriophages were able to replicate in intestinal sections and faeces homogenates from murine Previous in vitro studies have shown that enterocytes treated with TNF-α and IFN-γ, or infected with AIEC, express higher levels of the AIEC receptor CEACAM6. 48 Moreover, there is an increased colonization of the gut by AIEC in transgenic mice expressing human CEACAMs. 28, 48 Studies have further shown that AIEC express type 1 pili variant to increase the binding capacity to the abnormally high CEACAM6 expression found in the ileum of CD patients. 48, 49 CEACAM6 is known to be involved in AIEC-adherence and has been shown to be overexpressed in the ileum of CD patients. Sasaki et al. showed that there are alterations in CD enterocytes, leading to the ability of AIEC to adhere to a greater extent. 26 This was confirmed in an ex vivo study demonstrating that AIEC adhered only to enterocytes isolated from patients with CD, and not to enterocytes isolated from non-IBD patients. 28, 48 These results are in line with the findings of a pathological increase in CEACAM6 expression and AIEC affinity in CD patients. 30 Considering this, our next step was to investigate the involvement of CEACAM6 on LF82 uptake by the FAE of CD patients, ex vivo in Ussing chambers. Our results demonstrated that once the CEACAM6 receptor was blocked by anti-CEACAM6, LF82 translocation significantly decreased in FAE from patients with CD. Our results indicate that CEACAM6 is crucial for the uptake and translocation of LF82 through the mucosa, is expressed to a higher extent in FAE, and seems to be upregulated in CD patients compared with controls. The upregulation of CEACAM6 in FAE was supported by western blot analyses showing higher expressions in CD FAE compared with in FAE from controls; however, no significant difference could be seen in VE. In contrast, immunofluorescence confirmed higher CEACAM6 expression in VE, FAE, and adjacent-VE of CD patients compared with equivalent tissues from the ileum of controls. This highlights the value of the complementary techniques; a difference would be overlooked if immunoblotting only was used. These findings support the theory provided by Darfeuille-Michaud et al. that AIEC promote the colonization of the mucosa of CD patients by inducing an increased CEACAM6 expression via the induced secretion of TNF-α by infected macrophages. 48, 50 Interestingly, we showed a higher CEACAM6 expression in FAE than in VE of the same individual. This suggests that FAE has a face to the lumen with increased levels of CEACAM6, facilitating LF82 uptake. An alternative explanation for upregulation of CEACAM6 is the hypothesis that CEACAM6 is a part of the innate immunity. 51 In that case, it could play a protective role through trapping the invasive bacteria, and the whole complex of CEACAM6 and AIEC might then be released to the lumen from glycocalyx, hindering further invasion. 52 However, our results do not support this hypothesis, since we found a decreased LF82 translocation when blocking CEACAM6.
Previous in vitro studies indicate that several pathogenic E. coli strains influence the paracellular pathway by affecting tight junctions and ion transport in intestinal epithelia cells. 53, 54 In the present study, exposure to LF82 was found to increase paracellular permeability in CD patients but not in controls. This points to differential vulnerability of the mucosa, and probably refers to that LF82 can more easily enter the epithelium of patients with CD, compared to controls, and affect the tight junctions due to upregulated CEACAM6 expression. Speculatively, this upregulation could be an initiating mechanism for the increased paracellular permeability seen in patients with CD. Since LF82 had an effect on 51 Cr-EDTA permeability, and there was an effect on TER in vitro, one could have expected an effect on TER to also be seen in the ex vivo situation; however, TER ex vivo remained unchanged. This could relate to there being different regulation of permeability pathways, i.e. the leak and the pore pathways, 55 but could also be a result of differences in TER between subjects being small and conventional TER measurements not being sensitive enough to fully detect differences between tissues. 8, 35 In conclusion, as illustrated in Figure 8 , this study showed higher translocation of E. coli LF82 in patients with CD compared with controls, suggesting alterations in the barrier to LF82 in patients with CD. Our results further demonstrated that both bacterial LPF and host [CEACAM6] factors facilitate uptake and translocation of LF82, especially through the FAE. Our data provide insights into CD pathophysiology and might help elucidate and define novel therapeutic targets in CD to prevent recurrence before clinical symptoms and complications occur.
This article is dedicated to Professor Arlette Darfeuille-Michaud, in loving memory. 56, 57 
